July—Accuri Cytometers Inc. (cell analysis systems) has raised $6mm through its Series E venture round. There were 27 investors, including current shareholders Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures, and the InvestMichigan! Program (managed by Credit Suisse). The company will use the funds to expand commercialization efforts for its Accuri C6 Flow Cytometer system in the in vitro diagnostics market. Accuri already sells the product in the US, Europe, Asia, and South America.
July—Boston Heart Lab Corp. (diagnostics to monitor cardiovascular disease) has raised just over $10mm through its Series B round...